List of Alecensa drug patents
Alecensa is owned by Hoffmann-La Roche.
Alecensa contains Alectinib Hydrochloride.
Alecensa has a total of 5 drug patents out of which 0 drug patents have expired.
Alecensa was authorised for market use on 11 December, 2015.
Alecensa is available in capsule;oral dosage forms.
The generics of Alecensa are possible to be released after 24 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9126931 | HOFFMANN-LA ROCHE | Tetracyclic compound |
May, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(7 years from now) | |
| US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(9 years from now) | |
| US10350214 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(12 years from now) | |
| US11433076 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic